#obesity-treatment

#obesity-treatment

The OASIS 4 phase 3 trial, published in The New England Journal of Medicine, marks a major advance in Novo Nordisk's effort to expand obesity treatment options. Conducted over 64 weeks, the study compared once-daily oral semaglutide 25 mg plus lifestyle changes with a placebo in 307 adults who were obese or overweight and had at least one weight-related condition, but did not have diabetes.

Your donation allows us to keep sending journalists to speak to both sides of the story. The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.Your support makes all the difference.

The future of medicine will be personalized, taking patients' specific medical history into account when prescribing care. Hand-tailored treatment plans are especially crucial for issues as nuanced as obesity.

A study has been launched due to reports of serious side effects related to weight loss drugs potentially affecting the pancreas, prompting safety investigations.

Sheree's struggle emphasizes the increasing reliance on non-traditional methods for weight management amidst the challenges presented by GLP-1 therapies.

Pfizer's decision to halt danuglipron development underscores the risks and complexities involved in creating new obesity treatments, particularly after significant financial investment and testing phases.